24-Hour Intraocular Pressure (IOP) And Blood Pressure Control In Primary Open Angle Glaucoma (POAG) And Ocular Hypertension (OHT) Patients
Information source: Aristotle University Of Thessaloniki
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Primary Open Angle Glaucoma; Ocular Hypertension
Intervention: timolol maleate 0.5% (Drug); latanoprost/timolol fixed combination (Drug); placebo (artificial tears) (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Aristotle University Of Thessaloniki Official(s) and/or principal investigator(s):
AGP Konstas, MD, PhD, Principal Investigator, Affiliation: Glaucoma Unit, A University Dept of Ophthalmology, AHEPA Hospital
Summary
To compare the short-term mean 24-hour intraocular pressure (IOP) control, 24-hour blood
pressure (BP) effect and safety of Latanoprost/Timolol fixed combination given once in the
evening with placebo once in the morning versus timolol maleate 0. 5% given twice daily in
patients with ocular hypertension (OHT), and primary open-angle glaucoma (POAG).
Clinical Details
Study design: Treatment, Randomized, Double-Blind, Active Control, Crossover Assignment
Eligibility
Minimum age: 29 Years.
Maximum age: 80 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- POAG
- OHT
Exclusion Criteria:
- Advanced glaucoma
- Arterial Hypertension
Locations and Contacts
Glaucoma Unit, A University Dept of Ophthalmology, AHEPA Hospital, Thessaloniki 546 36, Greece
Additional Information
Starting date: April 2006
Ending date: April 2007
Last updated: May 7, 2008
|
